Vertex Pharmaceuticals
7 News & Press Releases found
Vertex Pharmaceuticals news
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a ste
May. 31, yyyy
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay has been elected to its board of directors as an independent director. Mr. Upadhyay
May. 18, yyyy
- New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built
- Facility to support continued R&D growth
At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, May. 17, yyyy
- Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes
- The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center
- Additional Vertex Foundation grant to Year Up to support health care workforce training
- Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study
- First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with initiation of Part B
- VX-880 generally well tolerated in all three patients dosed to date
- Ph
May. 2, yyyy
- Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®-
- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments-
- Single pivotal trial to initiate later this month targets the broad patient population with two APOL1 mutations and proteinuric kidney disease
- Pathway for accelerated approval using an interim analysis at Week 48 of eGFR slope, supported by reduction in proteinuria
- Final analysis evaluating eGFR slope at approximately two years serves as basis for U.S. approval